Download
CNCR-122-826.pdf 183,30KB
WeightNameValue
1000 Titel
  • Recommendations for a step‐wise comparative approach to the evaluation of new screening tests for colorectal cancer
1000 Autor/in
  1. Young, Graeme P |
  2. Senore, Carlo |
  3. Mandel, Jack S |
  4. Allison, James E |
  5. Atkin, Wendy S |
  6. Benamouzig, Robert |
  7. Bossuyt, Patrick M M |
  8. Silva, Mahinda De |
  9. Guittet, Lydia |
  10. Halloran, Stephen P |
  11. Hoff, Geir |
  12. Itzkowitz, Steven H |
  13. Leja, Marcis |
  14. Levin, Bernard |
  15. Meijer, Gerrit A |
  16. O'Morain, Colm A |
  17. Parry, Susan |
  18. Rabeneck, Linda |
  19. Rozen, Paul |
  20. Saito, Hiroshi |
  21. Schoen, Robert E |
  22. Seaman, Helen E |
  23. Steele, Robert J C |
  24. Sung, Joseph J Y |
  25. Winawer, Sidney J |
1000 Erscheinungsjahr 2016
1000 LeibnizOpen
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2016-02-01
1000 Erschienen in
1000 Quellenangabe
  • 122(6): 826-839
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2016
1000 Lizenz
1000 Verlagsversion
  • http://dx.doi.org/10.1002/cncr.29865 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066737/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: New screening tests for colorectal cancer continue to emerge, but the evidence needed to justify their adoption in screening programs remains uncertain. METHODS: A review of the literature and a consensus approach by experts was undertaken to provide practical guidance on how to compare new screening tests with proven screening tests. RESULTS: Findings and recommendations from the review included the following: Adoption of a new screening test requires evidence of effectiveness relative to a proven comparator test. Clinical accuracy supported by programmatic population evaluation in the screening context on an intention‐to‐screen basis, including acceptability, is essential. Cancer‐specific mortality is not essential as an endpoint provided that the mortality benefit of the comparator has been demonstrated and that the biologic basis of detection is similar. Effectiveness of the guaiac‐based fecal occult blood test provides the minimum standard to be achieved by a new test. A 4‐phase evaluation is recommended. An initial retrospective evaluation in cancer cases and controls (Phase 1) is followed by a prospective evaluation of performance across the continuum of neoplastic lesions (Phase 2). Phase 3 follows the demonstration of adequate accuracy in these 2 prescreening phases and addresses programmatic outcomes at 1 screening round on an intention‐to‐screen basis. Phase 4 involves more comprehensive evaluation of ongoing screening over multiple rounds. Key information is provided from the following parameters: the test positivity rate in a screening population, the true‐positive and false‐positive rates, and the number needed to colonoscope to detect a target lesion. CONCLUSIONS: New screening tests can be evaluated efficiently by this stepwise comparative approach.
1000 Sacherschließung
lokal screening test
lokal colorectal cancer
lokal colonoscopy
lokal fecal occult blood test
lokal molecular diagnostics
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/creator/WW91bmcsIEdyYWVtZSBQ|https://frl.publisso.de/adhoc/creator/U2Vub3JlLCBDYXJsbw==|https://frl.publisso.de/adhoc/creator/TWFuZGVsLCBKYWNrIFM=|https://frl.publisso.de/adhoc/creator/QWxsaXNvbiwgSmFtZXMgRQ==|https://frl.publisso.de/adhoc/creator/QXRraW4sIFdlbmR5IFM=|https://frl.publisso.de/adhoc/creator/QmVuYW1vdXppZywgUm9iZXJ0|https://frl.publisso.de/adhoc/creator/Qm9zc3V5dCwgUGF0cmljayBNIE0=|https://frl.publisso.de/adhoc/creator/U2lsdmEsIE1haGluZGEgRGU=|https://frl.publisso.de/adhoc/creator/R3VpdHRldCwgTHlkaWE=|https://frl.publisso.de/adhoc/creator/SGFsbG9yYW4sIFN0ZXBoZW4gUA==|https://frl.publisso.de/adhoc/creator/SG9mZiwgR2Vpcg==|https://frl.publisso.de/adhoc/creator/SXR6a293aXR6LCBTdGV2ZW4gSA==|https://frl.publisso.de/adhoc/creator/TGVqYSwgTWFyY2lz|https://frl.publisso.de/adhoc/creator/TGV2aW4sIEJlcm5hcmQ=|https://frl.publisso.de/adhoc/creator/TWVpamVyLCBHZXJyaXQgQQ==|https://frl.publisso.de/adhoc/creator/TydNb3JhaW4sIENvbG0gQQ==|https://frl.publisso.de/adhoc/creator/UGFycnksIFN1c2Fu|https://frl.publisso.de/adhoc/creator/UmFiZW5lY2ssIExpbmRh|https://frl.publisso.de/adhoc/creator/Um96ZW4sIFBhdWw=|https://frl.publisso.de/adhoc/creator/U2FpdG8sIEhpcm9zaGk=|https://frl.publisso.de/adhoc/creator/U2Nob2VuLCBSb2JlcnQgRQ==|https://frl.publisso.de/adhoc/creator/U2VhbWFuLCBIZWxlbiBF|https://frl.publisso.de/adhoc/creator/U3RlZWxlLCBSb2JlcnQgSiBD|https://frl.publisso.de/adhoc/creator/U3VuZywgSm9zZXBoIEogWQ==|https://frl.publisso.de/adhoc/creator/V2luYXdlciwgU2lkbmV5IEo=
1000 Label
1000 Förderer
  1. World Gastroenterology Organization |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer World Gastroenterology Organization |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6404109.rdf
1000 Erstellt am 2017-08-23T14:00:53.058+0200
1000 Erstellt von 122
1000 beschreibt frl:6404109
1000 Bearbeitet von 218
1000 Zuletzt bearbeitet 2022-06-03T18:38:27.474+0200
1000 Objekt bearb. Fri Jun 03 18:38:27 CEST 2022
1000 Vgl. frl:6404109
1000 Oai Id
  1. oai:frl.publisso.de:frl:6404109 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source